Biotech Start-Up Nexomics Biosciences Gets Off the Ground
News Jan 22, 2009
Nexomics Biosciences Inc., a recently-formed, New Jersey-based biotechnology company, applies platform technologies based on large scale protein production, Nuclear Magnetic Resonance (NMR), and X-ray crystallography for use in drug discovery efforts.
The company provides customers with services in bioinformatics, protein production and structural biology for lead discovery, optimization and development programs. In addition, Nexomics Biosciences will also pursue in-house drug discovery projects on proprietary targets to identify novel small molecule therapeutics.
Nexomics Biosciences has signed a comprehensive license agreement with Rutgers, the State University of New Jersey, that provides Nexomics rights to a portfolio of intellectual property, including a suite of bioinformatics software and an early stage antibiotic screening methodology.
In addition, the agreement gives Nexomics rights to use and further develop a novel ribosomal RNA methyltransferase assay for identifying specific binding and inhibition of R1mA proteins from bacterial species. The invention has applications in control of bacterial gene expression, control of bacterial growth, antibacterial chemistry, and antibacterial therapy.
An additional agreement has been announced with the Center for Advanced Biotechnology and Medicine (CABM), a research and teaching center that provides Nexomics access to laboratory space and equipment. Under the service agreement, Nexomics Biosciences will have access to a number of scientific facilities supporting molecular biology, fermentation, protein purification, and Nuclear Magnetic Resonance (NMR).
Computational Model Underlines Need for Personalised Approach to SepsisNews
A computational model of the human immune system has enabled researchers to explore the challenges of tackling sepsis.READ MORE